Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
HOXC11
REST API REST API
Homo sapiens
HOXC11 is differentially expressed in 155 experiments: 72 organism parts: lung, liver, ... (70 more);, 118 disease states: normal, Ewing sarcoma, ... (116 more);, 41 cell types 252 cell lines 21 compound treatments and 55 other conditions.
Synonyms HOX3H
Orthologs D4ACL0_RAT (Rattus norvegicus)   F1MZ11_BOVIN (Bos taurus)   Hoxc11 (Mus musculus)   HOXC11 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term regulation of transcription, DNA-dependent, proximal/distal pattern formation, sequence-specific DNA binding, endoderm development, multicellular organismal development, nucleus, metanephros development, embryonic digit morphogenesis, skeletal system development, sequence-specific DNA binding transcription factor activity, organ induction, anterior/posterior pattern specification
InterPro Term Homeobox, Homeobox_eu, DUF3528
UniProt Accession O43248
Search EB-eye ENSG00000123388
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-803, E-MTAB-24, E-MTAB-25, ... (16 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (25 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
HL-60
2
E-GEOD-5258, E-MTAB-37
SNU16
2
E-MTAB-37, E-GEOD-15460
BT474
1
2
E-MTAB-37, E-MEXP-440, E-MTAB-62
MDA-MB-231
1
2
E-TABM-420, E-MTAB-62, E-GEOD-5823
NCIH650
1
E-MTAB-37
246 more value(s).


Cell type

studied in E-GEOD-18811, E-AFMX-5, E-GEOD-20193, E-MTAB-24, E-MTAB-25, ... (22 experiments)

Factor Value U/D Experiments
2
E-TABM-145, E-TABM-130
hematopoietic
1
E-GEOD-9894
primary fibroblast
1
E-MEXP-66
adipocyte
1
E-AFMX-5
lung carcinoma
1
E-GEOD-17347
leydig cell
1
E-MTAB-25
35 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-TABM-15, E-GEOD-20602, ... (30 experiments)

Factor Value U/D Experiments
prostate cancer
2
E-GEOD-6919, E-MTAB-62
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
iatrogenic Kaposis sarcoma, KSHV-
1
E-MEXP-66
treated malaria, natural infection Cameroon
1
E-GEOD-5418
adjacent normal skin
1
E-GEOD-15101
teratozoospermia
1
E-GEOD-6872
112 more value(s).


Compound treatment

studied in E-GEOD-5824, E-GEOD-6462, E-MEXP-2590, E-MEXP-941, E-GEOD-5339, ... (13 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-941, E-MEXP-1335
none
1
2
E-GEOD-412, E-GEOD-5824, E-GEOD-2803
bacterial endotoxin
1
E-GEOD-3284
NaOH
1
E-MEXP-2590
epidermal growth factor
1
E-GEOD-6462
vanadium pentoxide
1
E-GEOD-5339
15 more value(s).


Biopsy tissue

studied in E-GEOD-5851

Factor Value U/D Experiments
rectal
1
E-GEOD-5851
adrenal gland; kidney
1
E-GEOD-5851


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-1563, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-GEOD-2666, ... (7 experiments)

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-3013

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Genetic modification
studied in E-GEOD-20847

Genotype
studied in E-GEOD-21750, E-TABM-321, E-TABM-601, E-GEOD-1153, E-GEOD-17347 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1446

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-19330, E-TABM-666, E-GEOD-6919, ... (18 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980, E-GEOD-6802 ... (5 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-21750

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

RNAi
studied in E-GEOD-1676, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.34 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM